Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors.

Background: Patients who developed immune-related adverse events (irAEs) could benefit more from treatment with immune checkpoint inhibitors (ICIs) than those who did not develop irAEs. This study was designed to assess whether the occurrence of irAEs or their characteristics are correlated with survival in advanced patients treated with ICIs.

Methods: This retrospective cohort study enrolled a panel of cancer patients who received ICIs at a single institute.

Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer.

Immune-related dissociated response (DR) has been recently recognized and have become a subject of ongoing interest. The purpose of the present study was to evaluate the frequency, treatment outcome, and predictors of DR in cancer patients with immune checkpoint inhibitors. We retrospectively collected clinicopathological data from a cohort of patients with cancer who received PD-1/PD-L1 inhibitor-based monotherapy or combination therapy at a single institution (developing cohort).

Design of an omnidirectional camouflage device with anisotropic confocal elliptic geometry in thermal-electric field.

The designed confocal elliptical core-shell structure can realize the omnidirectional camouflage effect without disturbing temperature and electric potential profiles as the directions of heat flux and electric current change. Based on the anisotropy of the confocal ellipse, the anisotropic effective parameters of the confocal elliptical core-shell structure are derived under different heat flux and electric current launching. Then, the matrix material should be anisotropic as the effective parameters to satisfy the omnidirectional camouflage effect, which is demonstrated numerically.